<DOC>
	<DOCNO>NCT01883544</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) multiple intravenous ( IV ) dose ALXN1007 healthy male female subject .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics ALXN1007 Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female ( childbearing potential ) subject ≥25 ≤55 year old . 2 . QTcF ≤450 msec ≤470 female . 3 . Willing able give write informed consent comply study visit schedule . 4 . Male subject female spouse/partner childbearing potential must use highly effective congraception1 consist two form birth control ( least one must barrier method ) start Screening continue end study . 1 . Highly effective contraception define : Established use oral , injected implant hormonal method contraception . Placement intrauterine device intrauterine system . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . 5 . Male subject must donate sperm start Screening end study . 6 . Documented vaccination meningococcal conjugate vaccine ( MCV4 ) least 14 day 5 year , prior dose . Female subject childbearing potential , include female experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopausal define : Amenorrhea ≥ 12 consecutive month without another cause document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL Female subject irregular menstrual period document serum FSH level &gt; 35 mIU/mL . Women hormone replacement therapy ( HRT ) . Women use oral contraceptive , hormonal contraceptive ( i.e. , vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( i.e. , diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( e.g. , vasectomy ) consider childbearing potential . 2 . Positive serum pregnancy test Screening Day 1 . 3 . Serum creatinine great upper limit normal ( ULN ) test laboratory Screening Day 1 . 4 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; ULN test laboratory Screening Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>ALXN1007</keyword>
	<keyword>Healthy Male Female Subjects</keyword>
</DOC>